Providers

Under the expanded FDA label, up to 1.8 million individuals in the United States could be eligible for sacubitril/valsartan, and up to 180,000 worsening heart failure (HF) events could be prevented or postponed.

A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.

In a study published in our December issue, researchers analyzed how prescribing of the newly approved heart failure drug sacubitril/valsartan diffused across the nation.

Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).

Three policies to revamp insurance consumer protections for health care delivery are explored, with highlighted areas for improvement being maternal health coverage and loosening of network adequacy requirements.

Patients with obstructive sleep apnea (OSA) exhibited similarly improved insomnia and quality-of-life outcomes when administered hypoglossal nerve stimulation (HNS) vs standard-of-care positive airway pressure (PAP) therapy.

An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses findings of the phase 3 ZUMA-7 trial presented at ASH 2021 and how use of axicabtagene ciloleucel can be optimally applied in a real-world setting.

Two-third of those who receive a chronic lymphocytic leukemia (CLL) diagnosis are age 65 or older, so the ease with which drugs are covered in Medicare has an outsized role in patient access to care.

Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.

Mark Wildgust, PhD, vice president, Global Medical Affairs, Oncology, Janssen, speaks on progression-free survival, complete response, and overall survival benefits observed with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 and other studies presented at the 63rd Annual American Society of Hematology Meeting and Exposition.

Two doses of the Pfizer vaccine may only have 22.5% efficacy against the Omicron variant; as of 2018, less than 16% of orthopedic specialists are people of color; a mask mandate for stores and indoor spaces in New York state went into effect.

Zanubrutinib produced prolonged progression-free survival (PFS) compared with a combination of bendamustine and rituximab among treatment-naïve patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL).

Investigators discuss the humoral response to enzyme-replacement therapy in their review of the clinical picture and diagnostic confirmation of Fabry disease.

Findings about the willingness of primary care providers to prescribe artificial pancreas systems have positive implications for increasing access to and reducing disparities around this technology by alleviating the need to see a specialist.

Posters review how a patient’s neighborhood impacts access to the liver transplant waitlist and how Medicaid expansion improved waitlist mortality.

High-flow nasal therapy overcomes some of the barriers associated with noninvasive ventilation, making the novel support beneficial for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD).

This new review examined oral health outcomes in children with growth hormone deficiency (GHD) following a search of the published literature from January 2000 through May 2021.

Guidelines recommend patients with nonalcoholic fatty liver disease (NAFLD) who are obese achieve 5% to 10% weight loss to prevent NAFLD progression.

Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, provides an overview of the emerging data at ASH 2021 on CAR T-cell therapy as a second- and first-line treatment.

This article describes the Philadelphia Medicaid Opioid Prescribing Initiative that was launched by a multidisciplinary team and mailed local Medicaid providers individualized prescribing report cards.

Findings presented today during EuroEcho 2021 demonstrate a potential link between persistent dyspnea following recovery from COVID-19 infection and subclinical cardiac dysfunction.

Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.

A high comorbidity burden, including psychiatric, autoimmune, and systemic conditions, was found in US adult ambulatory populations with atopic dermatitis.